Коллоидные системы доставки этопозида на основе биодеградируемых полимерных носителей (обзор литературы)
- Авторы: Меркулова М.А.1, Осипова Н.С.1, Калистратова А.В.1, Ермоленко Ю.В.1, Гельперина С.Э.1
-
Учреждения:
- Российский химико-технологический университет им. Д.И. Менделеева
- Выпуск: Том 85, № 5 (2023)
- Страницы: 593-618
- Раздел: Статьи
- URL: https://journals.rcsi.science/0023-2912/article/view/137229
- DOI: https://doi.org/10.31857/S0023291223600463
- EDN: https://elibrary.ru/DPYRBT
- ID: 137229
Цитировать
Аннотация
В обзоре рассмотрены системы доставки этопозида на основе коллоидных носителей – полимерных наночастиц и мицелл из синтетических и природных полимеров. Этопозид, ингибитор топоизомеразы II, занимает важное место в химиотерапии ряда опухолей, однако его применение часто ограничено ввиду выраженных побочных эффектов. Использование коллоидных систем доставки позволяет изменить фармакокинетические параметры этопозида и повысить его накопление в опухолях, что приводит к усилению противоопухолевого эффекта. Особый интерес представляют стимул-чувствительные системы, реагирующие на специфические условия в микроокружении опухоли, что позволяет значительно повысить селективность действия препарата.
Ключевые слова
Об авторах
М. А. Меркулова
Российский химико-технологический университет им. Д.И. Менделеева
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
Н. С. Осипова
Российский химико-технологический университет им. Д.И. Менделеева
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
А. В. Калистратова
Российский химико-технологический университет им. Д.И. Менделеева
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
Ю. В. Ермоленко
Российский химико-технологический университет им. Д.И. Менделеева
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
С. Э. Гельперина
Российский химико-технологический университет им. Д.И. Менделеева
Автор, ответственный за переписку.
Email: ma.merk@mail.ru
Россия, 125047, Москва, Миусская площадь, 9
Список литературы
- Hande K.R. Etoposide: Four decades of development of a topoisomerase II inhibitor // European Journal of Cancer. 1998. V. 34. № 10. P. 1514–1521. https://doi.org/10.1016/S0959-8049(98)00228-7
- Примерный перечень основных лекарственных средств, 21-й перечень, 2019 г. Копенгаген: Европейское региональное бюро ВОЗ; 2020. Лицензия: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/bitstream/handle/10665/331990/WHO-EURO-2020-476-40211-53802-rus.pdf?sequence=1&isAllowed=y.
- Agrawal K. Etoposide // xPharm: The Comprehensive Pharmacology Reference. 2007. P. 1–5. https://doi.org/10.1016/B978-008055232-3.61729-5
- Slevin M.L. The clinical pharmacology of etoposide // Cancer. 1991. V. 67. № S1. P. 319–329. https://doi.org/10.1002/1097-0142(19910101)67: 1+<319::AID-CNCR2820671319>3.0.CO;2-D
- Montecucco A., Zanetta F., Biamonti G. Molecular mechanisms of etoposide // EXCLI Journal. Leibniz Research Centre for Working Environment and Human Factors. 2015. V. 14. P. 95–108. https://doi.org/10.17179/excli2014-561
- Baldwin E.L., Osheroff N. Etoposide, topoisomerase II and cancer // Current Medicinal Chemistry-Anti-Cancer Agents. 2005. V. 5. № 4. P. 363–372. https://doi.org/10.2174/1568011054222364
- Kroschinsky F.P., Friedrichsen K., Mueller J. et al. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas // Cancer Chemother. Pharmacol. 2008. V. 61. P. 785–790. https://doi.org/10.1007/s00280-007-0535-3
- Shah J.C., Chen J.R., Chow D. Preformulation study of etoposide: Identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide // Pharmaceutical Research. 1989. V. 6. P. 408–412. https://doi.org/10.1023/A:1015935532725
- Siderov J., Prasad P., De Boer R., Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide // British Journal of Cancer. 2002. V. 86. № 1. P. 12–13. https://doi.org/10.1038/sj.bjc.6600003
- Hoetelmans R.M.W., Schornagel J.H., ten Bokkel Huinink W.W., Beijnen J.H. Hypersensitvity reactions to etoposide // Annals of Pharmacotherapy. 1996. V. 30. № 4. P. 367–371. https://doi.org/10.1177/106002809603000409
- Bernstein B.J., Troner M.B. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide // Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1999. V. 19. № 8. P. 989–991. https://doi.org/10.1592/phco.19.11.989.31566
- Zhao W. Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy // Nat. Prod. Rep. 2021. V. 38. № 3. P. 470–488. https://doi.org/10.1039/d0np00041h
- Махачева Ф.А., Валиев Т.Т. Особенности вторичного острого миелоидного лейкоза у детей // Онкогематология. 2020. Т. 15. № 4. С. 12–17. https://doi.org/10.17650/1818-8346-2020-15-4-12-17
- Zhang M., Hagan C.T., Foley H. et al. Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models // Acta Biomaterialia. 2021. V. 124. P. 327–335. https://doi.org/10.1016/j.actbio.2021.02.001
- Rafiyath S. M., Rasul M., Lee B., Wei G., Lamba G., Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis // Exp. Hematol. Oncol. 2012. V. 1. P. 1–10. https://doi.org/10.1186/2162-3619-1-10
- Фармакопея РФ. Требования к показателям качества и исследованию лекарственных средств на основе липосом, мицелл и лекарственных средств, содержащих покрытия из наночастиц. https://pharmacopoeia.ru/trebovaniya-k-pokazatelyam-kachestva-i-issledovaniyu-lekarstvennyh-sredstv-na-osnove-liposom-mitsell-ilekarsvtennyh-sredstv-soderzhashhih-pokrytiya-iz-nanochastits/#%D0%A0%D0%90%D0%97%D0%94%D0%95%D0%9B_2_%D0%A0%D0%B0%D0%B7%D1%80%D0%B0%D0%B1%D0%BE%D1%82%D0%BA%D0%B0_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2%D0%B5%D0%BD%D0%BD%D1%8B%D1%85_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D0%BE%D0%B2_%D0%BD%D0%B0_%D0%BE%D1%81%D0%BD%D0%BE%D0%B2%D0%B5_%D0%BC%D0%B8%D1%86%D0%B5%D0%BB%D0%BB_%D0%B1%D0%BB%D0%BE%D0%BA-%D1%81%D0%BE%D0%BF%D0%BE%D0%BB%D0%B8%D0%BC%D0%B5%D1%80%D0%BE%D0%B2 (обращение 20 июля 2022).
- US FDA. Drug Products, Including Biological Products, that Contain Nanomaterials. Guidance for Industry, April 2022. https://www.fda.gov/media/157812.
- Sindhwani S., Syed, A. M., Ngai J. et al. The entry of nanoparticles into solid tumours // Nature Materials. 2020. V. 19. № 5. P. 566–575. https://doi.org/10.1038/s41563-019-0566-2
- Malinovskaya J., Salami R., Valikhov M. et al. Supermagnetic human serum albumin (HSA) nanoparticles and PLGA-based doxorubicin nanoformulation: A duet for selective nanotherapy // Int. J. Mol. Sci. 2023. V. 24. P. 627.https://doi.org/10.3390/ijms24010627
- Yuan Z.Q., Chen W.L., You B.G. et al. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor // JCR. 2017. V. 268. P. 198–211. https://doi.org/10.1016/j.jconrel.2017.10.025
- Huang H.L., Lin W.J. Dual peptide-modified nanoparticles improve combination chemotherapy of etoposide and siPIK3CA against drug-resistant small cell lung carcinoma // Pharmaceutics. 2020. V. 12. № 3. P. 254. https://doi.org/10.3390/pharmaceutics12030254
- Bai J., Tian Y., Liu F. et al. Octreotide-conjugated core-cross-linked micelles with pH/redox responsivity loaded with etoposide for neuroendocrine neoplasms therapy and bioimaging with photoquenching resistance // ACS Appl Mater Interface. 2019. V. 11. № 20. P. 18111–18122. https://doi.org/10.1021/acsami.9b01827
- Kuo Y.C., Chang Y.H., Rajesh R. Targeted delivery of etoposide, carmustine and doxorubicin to human glioblastoma cells using methoxy poly(ethylene glycol)‑poly(ε‑caprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid // Mater. Sci. Eng. C. 2019. V. 96. P. 114–128. https://doi.org/10.1016/j.msec.2018.10.094
- Cohen Y., Levi M., Lesmes U., Margier M., Reboul E., Livney Y.D. Re-assembled casein micelles improve in vitro bioavailability of vitamin D in a Caco-2 cell model // Food & Function. 2017. V. 8. № 6. P. 2133–2141. https://doi.org/10.1039/c7fo00323d
- Naumenko V.A., Vlasova K.Y., Garanina A.S. et al. Extravasating neutrophils open vascular barrier and improve liposomes delivery to tumors // ACS Nano. 2019. V. 13. № 11. P. 12599–12612. https://doi.org/10.1021/acsnano.9b03848
- Lin Q., Fathi P., Chen X. Nanoparticle delivery in vivo: A fresh look from intravital imaging // EBioMedicine. 2020. V. 59. P. 102958. https://doi.org/10.1016/j.ebiom.2020.102958
- Golombek S.K. et al. Tumor targeting via EPR: Strategies to enhance patient responses // Advanced Drug Delivery Reviews. 2018. V. 130. P. 17–38. https://doi.org/10.1016/j.addr.2018.07.007
- Kakkar A., Traverso G., Farokhzad O.C., Weissleder R., Langer R. Evolution of macromolecular complexity in drug delivery systems // Nat. Rev. Chem. 2017. V. 1. № 8. P. 0063. https://doi.org/10.1038/s41570-017-0063
- Mitchell M.J., Billingsley M.M., Haley R.M. et al. Engineering precision nanoparticles for drug delivery // Nat. Rev. Drug Discov. 2021. V. 20. № 2. P. 101–124. https://doi.org/10.1038/s41573-020-0090-8
- Takechi-Haraya Y., Ohgita T., Demizu Y., Saito H., Izutsu K.I., Sakai-Kato K. Current status and challenges of analytical methods for evaluation of size and surface modification of nanoparticle-based drug formulations // AAPS PharmSciTech. 2022. V. 23. № 5. P. 150. https://doi.org/10.1208/s12249-022-02303-y
- Nel A.E., Mädler L., Velegol D. et al. Understanding biophysicochemical interactions at the nano–bio interface // Nature Materials. 2009. V. 8. № 7. P. 543–557. https://doi.org/10.1038/nmat2442
- Skalickova S., Nejdl L., Kudr J. et al. Fluorescence characterization of gold modified liposomes with antisense N-myc DNA bound to the magnetisable particles with encapsulated anticancer drugs (doxorubicin, ellipticine and etoposide) // Sensors. 2016. V. 16. № 3. P. 290. https://doi.org/10.3390/s16030290
- Mehrabi M., Esmaeilpour P., Akbarzadeh A. et al. Efficacy of pegylated liposomal etoposide nanoparticles on breast cancer cell lines // Turk. J. Med. Sci. 2016. V. 46. № 2. P. 567–571. https://doi.org/10.3906/sag-1412-67
- Deng W., Chen W., Clement S. et al. Controlled gene and drug release from a liposomal delivery platform triggered by X-ray radiation // Nat. Commun. 2018. V. 9. № 1. 2713. https://doi.org/10.1038/s41467-018-05118-3
- Varshosaz J., Hassanzadeh F., Sadeghi-Aliabadi H., Firozian F. Uptake of etoposide in CT-26 cells of colorectal cancer using folate targeted dextran stearate polymeric micelles // Biomed. Res. Int. 2014. V. 2014. https://doi.org/10.1155/2014/708593
- Qian W.Y., Sun D. M., Zhu R.R. et al. pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release // Int. J. Nanomedicine. 2012. P. 5781–5792. https://doi.org/10.2147/IJN.S34773
- Zhu R., Wang Q., Zhu Y. et al. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer // Acta Biomaterialia. 2016. V. 29. P. 320–332. https://doi.org/10.1016/j.actbio.2015.10.029
- Snehalatha M., Venugopal K., Saha R.N. Etoposide-loaded PLGA and PCL nanoparticles I: Preparation and effect of formulation variables // Drug Delivery. 2008. V. 15. № 5. P. 267–275. https://doi.org/10.1080/10717540802174662
- Yadav K.S., Chuttani K., Mishra A.K. et al. Long circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-pluronic block copolymers: Characterization, drug-release, blood-clearance, and biodistribution studies // Drug Dev. Res. 2010. V. 71. № 4. P. 228–239. https://doi.org/10.1002/ddr.20365
- Yadav K.S., Sawant K.K. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation // Curr. Drug Deliv. 2010. V. 7. № 1. P. 51–64. https://doi.org/10.2174/156720110790396517
- Wang Z., Li Z., Zhang D. et al. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery // Drug Delivery. 2015. V. 22. № 1. P. 79–85. https://doi.org/10.3109/10717544.2013.871600
- Kuo Y.C., Lee C.H. Inhibition against growth of glioblastoma multiforme in vitro using etoposide-loaded solid lipid nanoparticles with ρ-aminophenyl-α-D-manno-pyranoside and folic acid // J. Pharm. Sci. 2015. V. 104. № 5. P. 1804–1814. https://doi.org/10.1002/jps.24388
- Kuo Y.C., Wang I.H. Enhanced delivery of etoposide across the blood–brain barrier to restrain brain tumor growth using melanotransferrin antibody-and tamoxifen-conjugated solid lipid nanoparticles // J. Drug Target. 2016. V. 24. № 7. P. 645–654. https://doi.org/10.3109/1061186X.2015.1132223
- Jin G.W., Rejinold N.S., Choy J.H. Multifunctional polymeric micelles for cancer therapy // Polymers. 2022. V. 14. № 22. P. 4839. https://doi.org/10.3390/polym14224839
- Ahmad I., Pandit J., Sultana Y. et al. Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study // Mater. Sci. Eng. C. 2019. V. 100. P. 959–970. https://doi.org/10.1016/j.msec.2019.03.060
- Zhu Y., Zhu R., Wang M. et al. Anti-metastatic and anti-angiogenic activities of core–shell SiO2@LDH loaded with etoposide in non-small cell lung cancer // Advanced Science. 2016. V. 3. № 11. P. 1600229. https://doi.org/10.1002/advs.201600229
- Jo M.J., Shin H.J., Yoon M.S. et al. Evaluation of pH-sensitive polymeric micelles using citraconic amide bonds for the co-delivery of paclitaxel, etoposide, and rapamycin // Pharmaceutics. 2023. V. 15. № 1. P. 154. https://doi.org/10.3390/pharmaceutics15010154
- Abdel-Bar H.M., Walters A.A., Wang J.T.W., Al-Jamal K.T. Combinatory delivery of etoposide and siCD47 in a lipid polymer hybrid delays lung tumor growth in an experimental melanoma lung metastatic model // Adv. Healthc. Mater. 2021. V. 10. № 7. P. 2001853. https://doi.org/10.1002/adhm.202001853
- Maleki H., Naghibzadeh M., Amani A. et al. Preparation of paclitaxel and etoposide co-loaded MPEG-PL-GA nanoparticles: An investigation with artificial neural network // J. Pharm. Innov. 2021. V. 16. P. 11–25. https://doi.org/10.1007/s12247-019-09419-y
- Maleki H., Najafabadi M.R.H., Webster T.J. et al. Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma // Int. J. Pharm. 2021. V. 604. P. 120722. https://doi.org/10.1016/j.ijpharm.2021.120722
- Kovshova T., Mantrov S., Boiko S. et al. Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: Synergistic cytotoxicity in brain tumour cells // J. Microencapsul. 2023. V. 40. № 4. P. 246–262. https://doi.org/10.1080/02652048.2023.2188943
- Lim C., Ramsey J.D., Hwang D. et al. Drug-dependent morphological transitions in spherical and worm-like polymeric micelles define stability and pharmacological performance of micellar drugs // Small. 2022. V. 18. № 4. P. 2103552. https://doi.org/10.1002/smll.202103552
- Rezvantalab S., Drude N.I., Moraveji M.K. et al. P-LGA-based nanoparticles in cancer treatment // Front. Pharmacol. 2018. V. 9. P. 1260. https://doi.org/10.3389/fphar.2018.01260
- Casalini T., Rossi F., Castrovinci A., Perale G. A Perspective on polylactic acid-based polymers use for nanoparticles synthesis and applications // Front. Bioeng. Biotechnol. 2019. V. 7. P. 259. https://doi.org/10.3389/fbioe.2019.00259
- Operti M.C., Bernhardt A., Grimm S. et al. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up // Int. J. Pharm. 2021. V. 605. P. 120807. https://doi.org/10.1016/j.ijpharm.2021.120807
- Park K., Otte A., Sharifi F. et al. Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles // Journal of Controlled Release. 2021. V. 329. P. 1150–1161. https://doi.org/10.1016/j.jconrel.2020.10.044
- Callewaert M., Dukic S., Van Gulick L. et al. Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency // J. Biomed. Mater. Res. A. 2013. V. 101 A. № 5. P. 1319–1327. https://doi.org/10.1002/jbm.a.34442
- Saadati R., Dadashzadeh S. Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: In vitro and in vivo evaluation // Int. J. Pharm. 2014. V. 464. № 1–2. P. 135–144. https://doi.org/10.1016/j.ijpharm.2014.01.014
- Yadav K.S., Jacob S., Sachdeva G., Sawant K.K. Intracellular delivery of etoposide loaded biodegradable nanoparticles: Cytotoxicity and cellular uptake studies // J. Nanosci. Nanotechnol. 2011. V. 11. № 8. P. 6657–6667. https://doi.org/10.1166/jnn.2011.4225
- Rivas C.J.M., Tarhini M., Badri W. et al. Nanoprecipitation process: From encapsulation to drug delivery // Int. J. Pharm. 2017. V. 532. № 1. P. 66–81. https://doi.org/10.1016/j.ijpharm.2017.08.064
- Callewaert M., Dukic S., Van Gulick L. et al. Etoposide encapsulation in surface-modified poly (lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency // J. Biomed. Mater. Res. A. 2013. V. 101. № 5. P. 1319–1327. https://doi.org/10.1002/jbm.a.34442
- Kovshova T., Osipova N., Alekseeva A. et al. Exploring the interplay between drug release and targeting of lipid-like polymer nanoparticles loaded with doxorubicin // Molecules. 2021. V. 26. № 4. P. 831. https://doi.org/10.3390/molecules26040831
- Stipa P., Marano S., Galeazzi R. et al. Prediction of drug-carrier interactions of PLA and PLGA drug-loaded nanoparticles by molecular dynamics simulations // Eur. Polym. J. 2021. V. 147. P. 110292. https://doi.org/10.1016/j.eurpolymj.2021.110292
- Ермоленко Ю.В., Семёнкин А.С., Ульянова Ю.В., Ковшова Т.С., Максименко О.О., Гельперина С.Э. Роль гидролитической деградации полилактидных носителей при разработке нано- и микроразмерных лекарственных форм на их основе // Известия Академии наук. Серия химическая. 2020. Т. 8. С. 1416–1427.
- D’Souza S.A. Review of in vitro drug release test methods for nano-sized dosage forms // Advances in pharmaceutics. 2014. V. 2014. P. 1–12. https://doi.org/10.1155/2014/304757
- Pimple S., Manjappa A.S., Ukawala M., Murthy R.S.R. PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: In vitro cell line study to ensure advantage of combination therapy // Cancer Nanotechnol. 2012. V. 3. P. 25–36. https://doi.org/10.1007/s12645-012-0027-y
- Yadav R., Kumar D., Kumari A. et al. Encapsulation of podophyllotoxin and etoposide in biodegradable poly-D,L-lactide nanoparticles improved their anticancer activity // J. Microencapsul. 2014. V. 31. № 3. P. 211–219. https://doi.org/10.3109/02652048.2013.834988
- Singh V., Sahebkar A., Kesharwani P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery // Eur. Polym. J. 2021. V. 158. P. 110683. https://doi.org/10.1016/j.eurpolymj.2021.110683
- Посыпанова Г.А., Горшкова Л.Б., Родина А.В. и др. Характеристика противоопухолевой активности полимерной формы этопозида в составе биодеградируемого сополимера молочной и гликолевой кислот // Химико-фармацевтический журнал. 2016. P. 45–49.
- Mitra M., Dilnawaz F., Misra R. et al. Toxicogenomics of nanoparticulate delivery of etoposide: Potential impact on nanotechnology in retinoblastoma therapy // Cancer Nanotechnol. 2011. V. 2. № 1–6. P. 21–36. https://doi.org/10.1007/s12645-010-0010-4
- Schaefer M.J., Singh J. Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres // Biomaterials. 2002. V. 23. № 16. P. 3465–3471. https://doi.org/10.1016/S0142-9612(02)00053-4
- Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective // Annu. Rev. Pharmacol. 2012. V. 52. P. 481–503. https://doi.org/10.1146/annurev-pharmtox-010611-134623
- Yadav K.S., Chuttani K., Mishra A.K., Sawant K.K. Effect of size on the biodistribution and blood clearance of etoposide-loaded PLGA nanoparticles // PDA J. Pharm. Sci. Technol. 2011. V. 65. № 2. P. 131–139.
- Snehalatha M., Kolachina V., Saha R.N. et al. Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton’s lymphoma tumor bearing mice // J. Pharm. Bioallied Sci. 2013. V. 5. № 4. P. 290–297. https://doi.org/10.4103/0975-7406.120081
- Sarfarazi A., Lee G., Mirjalili S.A. et al. Therapeutic delivery to the peritoneal lymphatics: Treatment benefits and future prospects // Int. J. Pharm. 2019. V. 567. P. 118456. https://doi.org/10.1016/j.ijpharm.2019.118456
- Lee G., Han S., Inocencio I., Cao E. et al. Lymphatic uptake of liposomes after intraperitoneal administration primarily occurs via the diaphragmatic lymphatics and is dependent on liposome surface properties // Mol. Pharm. 2019. V. 16. № 12. P. 4987–4999. https://doi.org/10.1021/acs.molpharmaceut.9b00855
- Malinovskaya Y., Melnikov P., Baklaushev V. et al. Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells // Int. J. Pharm. 2017. V. 524. № 1–2. P. 77–90. https://doi.org/10.1016/j.ijpharm.2017.03.049
- Kuo Y.C., Chen Y.C. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles // Int. J. Pharm. 2015. V. 479. № 1. P. 138–149. https://doi.org/10.1016/j.ijpharm.2014.12.070
- Lagas J.S., Fan L., Wagenaar E. et al. P-Glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide // Clin. Cancer Res. 2010. V. 16. № 1. P. 130–140. https://doi.org/10.1158/1078-0432.CCR-09-1321
- Kuplennik N., Lang K., Steinfeld R., Sosnik A. Folate receptor α-modified nanoparticles for targeting of the central nervous system // ACS Appl. Mater. Interface. 2019. V. 11. № 43. P. 39633–39647. https://doi.org/10.1021/acsami.9b14659
- Godse R., Rathod M., De A., Shinde U. Intravitreal galactose conjugated polymeric nanoparticles of etoposide for retinoblastoma // J. Drug Deliv. Sci. Technol. 2021. V. 61. P. 102259. https://doi.org/10.1016/j.jddst.2020.102259
- Pan J., Rostamizadeh K., Filipczak N., Torchilin V.P. Polymeric co-delivery systems in cancer treatment: An overview on component drugs' dosage ratio effect // Molecules. 2019. V. 24. № 6. P. 1035. https://doi.org/10.3390/molecules24061035
- Fatma S., Talegaonkar S., Iqbal Z. et al. Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: An in vitro, ex vivo and in vivo investigations // Drug Delivery. 2016. V. 23. № 2. P. 500–511. https://doi.org/10.3109/10717544.2014.923956
- Espinoza S.M., Patil H.I., San Martin Martinez E., Casañas Pimentel R., Ige P.P. Poly-ε-caprolactone (PCL), a promising polymer for pharmaceutical and biomedical applications: Focus on nanomedicine in cancer // Int. J. Polym. Mater. 2020. V. 69. № 2. P. 85–126. https://doi.org/10.1080/00914037.2018.1539990
- Kalita N.K., Bhasney S.M., Mudenur C. et al. End-of-life evaluation and biodegradation of poly(lactic acid)(PLA)/polycaprolactone (PCL)/microcrystalline cellulose (MCC) polyblends under composting conditions // Chemosphere. 2020. V. 247. P. 125875. https://doi.org/10.1016/j.chemosphere.2020.125875
- Vivek K., Harivardhan Reddy L., Murthy R.S.R. Comparative study of some biodegradable polymers on the entrapment efficiency and release behavior of etoposide from microspheres // Pharm. Dev. Technol. 2007. V. 12. № 1. P. 79–88. https://doi.org/10.1080/10837450601168581
- Kuo Y.C., Wang I.H. Using catanionic solid lipid nanoparticles with wheat germ agglutinin and lactoferrin for targeted delivery of etoposide to glioblastoma multiforme // J. Taiwan Inst. Chem. Eng. 2017. V. 77. P. 73–82. https://doi.org/10.1016/j.jtice.2017.05.003
- Xu Y., Tang L., Liu Y. et al. Dual-modified albumin-polymer nanocomplexes with enhanced in vivo stability for hepatocellular carcinoma therapy // Colloids Surf. B. 2021. V. 201. P. 111642. https://doi.org/10.1016/j.colsurfb.2021.111642
- Xie P., Yan J., Wu M. et al. CD44 potentiates hepatocellular carcinoma migration and extrahepatic metastases via the AKT/ERK signaling CXCR4 axis // Annals of Translational Medicine. 2022. V. 10. № 12. P. 689. https://doi.org/10.21037/atm-22-2482
- Spada A., Emami J., Tuszynski J.A., Lavasanifar A. The uniqueness of albumin as a carrier in nanodrug delivery // Mol. Pharm. 2021. V. 18. № 5. P. 1862–1894. https://doi.org/10.1021/acs.molpharmaceut.1c00046
- Manjushree M., Revanasiddappa H.D. Evaluation of binding mode between anticancer drug etoposide and human serum albumin by numerous spectrometric techniques and molecular docking // Chemical Physics. 2020. V. 530. P. 110593. https://doi.org/10.1016/j.chemphys.2019.110593
- Akdogan Y., Reichenwallner J., Hinderberger D. Evidence for water-tuned structural differences in proteins: An approach emphasizing variations in local hydrophilicity // PLOS One. 2012. V. 7. https://doi.org/10.1371/journal.pone.0045681
- Osipova N., Budko A., Maksimenko O. et al. Comparison of compartmental and non-compartmental analysis to detect biopharmaceutical similarity of intravenous nanomaterial-based rifabutin formulations // Pharmaceutics. 2023. V. 15. № 4. P. 1258. https://doi.org/10.3390/pharmaceutics15041258
- Elgohary M.M., Helmy M.W., Mortada S.M., Elzoghby A.O. Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer // Nanomedicine. 2018. V. 13. № 17. P. 2221–2224. https://doi.org/10.2217/nnm-2018-0097
- Narayana R.V.L., Jana P., Tomar N. et al. Carboplatin- and etoposide-loaded lactoferrin protein nanoparticles for targeting cancer stem cells in retinoblastoma in vitro // IOVS. 2021. V. 62. № 14. P. 13. https://doi.org/10.1167/iovs.62.14.13
- Akbal Ö., Erdal E., Vural T. et al. Comparison of protein- and polysaccharide-based nanoparticles for cancer therapy: Synthesis, characterization, drug release, and interaction with a breast cancer cell line // Artificial Cells, Nanomedicine, and Biotechnology. 2017. V. 45. № 2. P. 193–203. https://doi.org/10.3109/21691401.2016.1170694
- Raval N., Maheshwari R., Shukla H. et al. Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer // Mater. Sci. Eng. C. 2021. V. 126. P. 112186. https://doi.org/10.1016/j.msec.2021.112186
- Hwang D., Ramsey J.D., Kabanov A.V. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval // Adv. Drug Deliv. Rev. 2020. V. 156. P. 80–118. https://doi.org/10.1016/j.addr.2020.09.009
- Mohanty A.K., Dilnawaz F., Mohanty C., Sahoo S.K. Etoposide-loaded biodegradable amphiphilic methoxy (poly ethylene glycol) and poly (epsilon caprolactone) copolymeric micelles as drug delivery vehicle for cancer therapy // Drug Delivery. 2010. V. 17. № 5. P. 330–342. https://doi.org/10.3109/10717541003720688
- Letchford K., Liggins R., Burt H. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: Theoretical and experimental data and correlations // J. Pharm. Sci. 2008. V. 97. № 3. P. 1179–1190. https://doi.org/10.1002/jps.21037
- Chen L., Tan L., Zhang X. et al. Which polymer is more suitable for etoposide: A comparison between two kinds of drug loaded polymeric micelles in vitro and in vivo? // Int. J. Pharm. 2015. V. 495. № 1. P. 265–275. https://doi.org/10.1016/j.ijpharm.2015.08.043
- Ukawala M., Rajyaguru T., Chaudhari K. et al. Investigation on design of stable etoposide-loaded PEG-PCL micelles: Effect of molecular weight of PEG-PCL diblock copolymer on the in vitro and in vivo performance of micelles // Drug Delivery. 2012. V. 19 № 3. P. 155–167. https://doi.org/10.3109/10717544.2012.657721
- Shin H.C., Alani A.W., Rao D.A., Rockich N.C., Kwon G.S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs // J. Control Release. 2009. V. 140. № 3. P. 294–300. https://doi.org/10.1088/1361-6528/aa66ba
- Tsend-Ayush A., Zhu X., Ding Y., Yao J., Yin L., Zhou J., Yao J. Lactobionic acid-conjugated TPGS nanoparticles for enhancing therapeutic efficacy of etoposide against hepatocellular carcinoma // Nanotechnology. 2017. V. 28. № 19. P. 195602. https://doi.org/10.1088/1361-6528/aa66ba
- Zhu X., Tsend-Ayush A., Yuan Z. et al. Glycyrrhetinic acid-modified TPGS polymeric micelles for hepatocellular carcinoma-targeted therapy // Int. J. Pharm. 2017. V. 529. № 1–2. P. 451–464. https://doi.org/10.1016/j.ijpharm.2017.07.011
- Varshosaz J., Hassanzadeh F., Sadeghi H., Firozian F., Mirian M. Optimization of self-assembling properties of fatty acids grafted to methoxy poly(ethylene glycol) as nanocarriers for etoposide // Acta Pharm. 2012. V. 62. № 1. P. 31–44. https://doi.org/10.2478/v10007-012-0006-1
- Mudhakir D., Sukmadjaja S.A., Yeyet C.S. Packaging the alkaloids of cinchona bark in combination with etoposide in polymeric micelles nanoparticles // Int. J. Pharm. Sci. 2012. V. 6. № 12. P. 685–689. https://doi.org/10.5281/zenodo.1327853
- Na H.S., Lim Y.K., Jeong Y.I., Lee H.S., Lim Y.J., Kang M.S., Cho C.S., Lee H.C. Combination antitumor effects of micelle-loaded anticancer drugs in a CT-26 murine colorectal carcinoma model // Int. J. Pharm. 2010. V. 383. № 1–2. P. 192–200. https://doi.org/10.1016/j.ijpharm.2009.08.041
- Lim C., Dismuke T., Malawsky D. et al. Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq–guided combination with sapanisertib // Sci. Adv. 2022. V. 8. № 4. P. eabl5838. https://doi.org/10.1126/sciadv.abl5838
- Wan X., Min Y., Bludau H., Keith A., Sheiko S.S., Jordan R., Wang A.Z., Sokolsky-Papkov M., Kabanov A.V. Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer // ACS Nano. 2018. V. 12. № 3. P. 2426–2439. https://doi.org/10.1021/acsnano.7b07878
- Kim J.-H., Emoto K., Iijima M., Nagasaki Y., Aoyagi T., Okano T., Sakurai Y., Kataoka K. Core-stabilized polymeric micelle as potential drug carrier: Increased solubilization of taxol // Polym. Adv. Technol. 1999. V. 10. № 11. P. 647–654. https://doi.org/10.1002/(SICI)1099-1581(199911)10: 11<647::AID-PAT918>3.0.CO;2-Y
- Wang F., Bronich T.K., Kabanov A.V., Rauh R.D., Roovers J. Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier // Bioconjug. Chem. 2005. V. 16. № 2. P. 397–405. https://doi.org/10.1021/bc049784m
- Wang F., Bronich T.K., Kabanov A.V., Rauh R.D., Roovers J. Synthesis and characterization of star poly(epsilon-caprolactone)-b-poly(ethylene glycol) and poly(L-lactide)-b-poly(ethylene glycol) copolymers: Evaluation as drug delivery carriers // Bioconjug. Chem. 2008. V. 19. № 7. P. 1423–1429. https://doi.org/10.1021/bc7004285
- Ukawala M., Rajyaguru T., Chaudhari K., Manjappa A.S., Murthy R.S.R., Gude R. EILDV-conjugated, etoposide-loaded biodegradable polymeric micelles directing to tumor metastatic cells overexpressing α4β1 integrin // Cancer Nanotechnology. 2011. V. 2. P. 133–145. https://doi.org/10.1007/s12645-011-0023-7
- Luiz M.T., Di Filippo L.D., Alves R.C. et al. The use of TPGS in drug delivery systems to overcome biological barriers // Eur. Polym. J. 2021. V. 142. P. 110129. https://doi.org/10.1016/j.eurpolymj.2020.110129
- Lagarrigue P., Moncalvo F., Cellesi F. Non-spherical polymeric nanocarriers for therapeutics: The effect of shape on biological systems and drug delivery properties // Pharmaceutics. 2023. V. 15. № 1. P. 32. https://doi.org/10.3390/pharmaceutics15010032
- Kennedy L., Sandhu J.K., Harper M.E., Cuperlovic-Culf M. Role of glutathione in cancer: From mechanisms to therapies // Biomolecules. 2020. V. 10. № 10. P. 1429. https://doi.org/10.3390/biom10101429
- Jo M.J., Shin H.J., Yoon M.S. et al. Evaluation of pH-sensitive polymeric micelles using citraconic amide bonds for the co-delivery of paclitaxel, etoposide, and rapamycin // Pharmaceutics. 2023. V. 15. № 1. P. 154. https://doi.org/10.3390/pharmaceutics15010154
- Varshosaz J., Hassanzadeh F., Sadeghi H., Firozian F., Mirian M. Effect of molecular weight and molar ratio of dextran on self-assembly of dextran stearate polymeric micelles as nanocarriers for etoposide // J. Nanomater. 2012. V. 2012. P. 120. https://doi.org/10.1155/2012/265657
- Agwa M.M., Abu-Serie M.M., Abdelmonsif D.A., Moussa N., Elsayed H., Khattab S.N., Sabra S. Vitamin D3/phospholipid complex decorated caseinate nanomicelles for targeted delivery of synergistic combination therapy in breast cancer // Int. J. Pharm. 2021. V. 607. 120965. https://doi.org/10.1016/j.ijpharm.2021.120965
- Carlberg C., Muñoz A. An update on vitamin D signaling and cancer // Seminars in Cancer Biology. 2022. V. 79. P. 217–230. https://doi.org/10.1016/j.semcancer.2020.05.018
- Gaber M., Elhasany K.A. et al. Co-administration of tretinoin enhances the anti-cancer efficacy of etoposide via tumor-targeted green nano-micelles // Colloids Surf. B. Biointerfaces. 2020. V. 192. P. 110997. https://doi.org/10.1016/j.colsurfb.2020.110997
- Alliot J., Theodorou I., Nguyen D.V., Forier C., Ducongé F., Grave E., Doris E. Tumor targeted micellar nanocarriers assembled from epipodophyllotoxin-based amphiphiles // Nanoscale. 2019. V. 11. № 19. P. 9756–9759. https://doi.org/10.1039/C9NR01068H
- Alliot J., Theodorou I., Ducongé F., Gravel E., Doris E. Polyamine transport system-targeted nanometric micelles assembled from epipodophyllotoxinamphiphiles // Chemical Communications. 2019. V. 55. № 99. P. 14968–14971. https://doi.org/10.1039/c9cc07883e
- Leonard A., Wolff J.E. Etoposide improves survival in high-grade glioma: A meta-analysis // Anticancer Research. 2013. V. 33. № 8. P. 3307–3315.
- Mehta A., Awah C.U., Sonabend A.M. Topoisomera-se II poisons for glioblastoma; Existing challenges and opportunities to personalize therapy // Frontiers in Neurology. 2018. V. 9. P. 459. https://doi.org/10.3389/fneur.2018.00459
- Lagas J.S., Fan L., Wagenaar E., Vlaming M.L., van Tellingen O., Beijnen J.H., Schinkel A.H. P-Glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide // Clin. Cancer Res. 2010. V. 16 № 1. P. 130–140. https://doi.org/10.1158/1078-0432.CCR-09-1321
- Bart J., Groen H.J., van der Graaf W.T., Hollema H., Hendrikse N.H., Vaalburg W., Sleijfer D.T., de Vries E.G. An oncological view on the blood−testis barrier // The Lancet Oncology. 2002. V. 3. № 6. P. 357–363. https://doi.org/10.1016/s1470-2045(02)00776-3